4896 — K Pharma Income Statement
0.000.00%
- ¥10bn
- ¥7bn
- ¥1bn
- 51
- 11
- 66
- 35
Annual income statement for K Pharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | Yuho |
Standards: | JAS | JAS | JAS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0 | 0 | 1,000 |
Cost of Revenue | |||
Gross Profit | — | — | 910 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 228 | 385 | 687 |
Operating Profit | -228 | -385 | 313 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -229 | -391 | 301 |
Provision for Income Taxes | |||
Net Income After Taxes | -229 | -392 | 260 |
Net Income Before Extraordinary Items | |||
Net Income | -229 | -392 | 260 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -229 | -392 | 260 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -19.3 | -32.2 | 26.4 |
Dividends per Share |